The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly: Clinical Pharmacokinetic Evaluation in Patients With Schizophrenia (Preliminary Data)

PURPOSE/BACKGROUND: The aim of the study was a preliminary evaluation of the maintenance of clinical efficacy and tolerability of paliperidone palmitate in patients with schizophrenia during the transition phase from 1-monthly paliperidone palmitate formulation (PP1M) to PP3M, with the evaluation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mauri, Massimo Carlo, Franco, Gemma, Minutillo, Alessandro, Paletta, Silvia, Di Pace, Chiara, Reggiori, Alessandra, Baldelli, Sara, Cattaneo, Dario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907683/
https://www.ncbi.nlm.nih.gov/pubmed/34840286
http://dx.doi.org/10.1097/JCP.0000000000001484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907683/
https://www.ncbi.nlm.nih.gov/pubmed/34840286
http://dx.doi.org/10.1097/JCP.0000000000001484

Ejemplares similares